Lunaria-rediviva schreef op 8 april 2021 11:50:
[...]
Hallo De Monitor,
Ik denk dat hij bedoeld dat doorbraakaanvallen in de profylaxe therapieën juist heftiger kunnen zijn als ze optreden en dat ze niet behandeld kunnen worden, of minder efficiënt met een soortgelijk product en dus Ruconest meer gebruikt gaat worden.
Misschien is dit niet waar hij op doelt. Zo niet mijn excuus, maar het zou dan jullie beide sieren om jullie bron te vermelden zodat ook andere hier toegang tot kunnen hebben om mee te doen in de discussie.
Hieronder een verduidelijking van mijn bijdrage met markering en met bron:
finance.yahoo.com/news/edited-transcr...Edited Transcript of PHAR.AS earnings conference call or presentation 4-Mar-21"So whilst RUCONEST is approved for acute use, we see, of course, a lot of patients that are currently going and are under prophylactic treatments in the U.S. market. Now the good news for the patients is that these new prophylactic treatments offer better attack reduction rates than the previous plasma-derived C1 inhibitor prophylaxis treatment. But still, according to published data, approximately half of these patients using those new prophylactic treatments continue to have breakthrough attacks. Some frequently and others less frequently, but they are from time to time, of course, and some more frequently, like I said, in need of regular use of breakthrough medication. And of course, according to their treatment plans, they should have breakthrough medication at hand at all times.
And although the bradykinin-kallikrein inhibitors that are often used and in the past were standard use for breakthrough medications, they block the same pathway for symptomatology, the bradykinin-kallikrein pathway that are the prophylactic treatments are actually covering. Noncontrolled breakthrough attack can and does occur from time to time or sometimes more frequently and becomes then very serious if they have no C1 inhibitor therapy anymore available, because they don't have their C1 inhibitor prophylactic therapy at hand anymore. So we see there that increasingly, with the shift to the new paradigm for prophylaxis and the increased recognition for this prophylaxis patient starts to exist to have effective and reliable C1 inhibitor treatment for breakthrough attacks at hand. And we see, therefore,
that new generational prophylactic therapies like the monoclonal antibody that is blocking the bradykinin-kallikrein pathway, also the new oral product that has recently been launched for -- and that is blocking the bradykinin-kallikrein pathway. We see, therefore, an additional growth opportunity for RUCONEST for the treatment of those breakthrough attacks that are associated with those prophylactic products."